Advanced pancreatic carcinoma: current treatment and future challenges
By A. Stathis, M. Moore. Nature Reviews Clinical Oncology, 2010
801 citations recorded by the source corpus.
Subfields: Cancer Research, Oncology
View Paper: https://www.semanticscholar.org/paper/edbd6f9819e0b9eb653ba8e6584c6bf6fab3a33a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Oncology
Citations in the corpus
- CANCER-ASSOCIATED FIBROBLAST EXOSOMES REGULATE SURVIVAL AND PROLIFERATION OF PANCREATIC CANCER CELLS (2016, neutral): “Pancreatic ductal adenocarcinoma (PDAC) has a dismal 5-year survival rate of less than 7% (1).”
- Hypoxic Tumor-Derived Exosomal miR-301a Mediates M2 Macrophage Polarization via PTEN/PI3Kγ to Promote Pancreatic Cancer Metastasis. (2018, background): “The high mortality in patients with pancreatic cancer is mainly ascribed to the difficult diagnosis at the early stage, aggressive local invasion, and early metastasis (4, 5).”
- A Distinct Replication Fork Protection Pathway Connects Fanconi Anemia Tumor Suppressors to RAD51-BRCA1/2 (2012, background): “These include agents that induce DNA lesions, such as camptothecin and cisplatin, as well as those that stall replication progression by perturbing the composition and/or concentration of nucleotide pools, such as gemcitabine and 5-fluorouracil (Stathis and Moore, 2010).”
- A patient-level meta-analysis of FOLFIRINOX for locally advanced pancreatic cancer (2016, background): “(1, 2) At the time of diagnosis, about 15% of patients have resectable disease (stage I or II), 35% locally advanced pancreatic cancer (LAPC, stage III), and 50% metastatic disease (stage IV).(3) The diagnosis of resectable disease and LAPC is determined by the extent of tumor contact with the super”
- Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy (2011, background): “Overall survival is typically 6 months from diagnosi”